MDMA辅助心理治疗退伍军人、消防员和警察创伤后应激障碍的随机双盲剂量反应2期试验
这项在美国门诊精神科诊所开展的随机双盲剂量反应2期试验,纳入26名慢性PTSD退伍军人和一线急救人员,按1:1:2随机接受30mg、75mg或125mg MDMA辅助心理治疗。
核心结论
- 在受控环境中,75mg和125mg活性剂量MDMA辅助心理治疗对退伍军人和一线急救人员的PTSD症状有效且耐受良好。
研究设计与样本
- 在美国门诊精神科诊所开展的随机、双盲、剂量反应2期试验,纳入26名18岁及以上、慢性PTSD病程≥6个月且CAPS-IV总分≥50的退伍军人和一线急救人员。
- 参与者按1:1:2随机分配至30mg(活性对照,n=7)、75mg(n=7)或125mg(n=12)MDMA加心理治疗组,MDMA口服给药,共两次8小时会话并辅以手册化心理治疗。
- 主要终点为第二次实验会话后1个月CAPS-IV总分较基线的平均变化;30mg和75mg组随后进入开放标签交叉,接受三次100-125mg MDMA辅助心理治疗会话。
主要发现
- 20名参与者报告85例不良事件,其中4例(5%)为严重不良事件:3例判定无关,1例可能与研究药物治疗相关。
关键数值与推荐
- 纳入标准:年龄≥18岁、慢性PTSD病程≥6个月、CAPS-IV总分≥50的退伍军人和一线急救人员。
- 随机分配比例1:1:2至30mg、75mg或125mg MDMA加心理治疗组。
- 主要终点为第二次实验会话后1个月CAPS-IV总分较基线的平均变化。
临床怎么用
- 结果提示在受控临床环境中,75mg和125mg MDMA辅助心理治疗可作为退伍军人和一线急救人员慢性PTSD的潜在治疗选择。
- 治疗需在具备安全监测条件的受控环境中进行,关注不良事件、生命体征及自杀意念和行为。
局限性
- 原文未报告样本量计算的依据或把握度分析。
- 原文未报告盲法揭盲后的具体偏倚评估细节。
- 原文未报告不同剂量组间基线特征的详细比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first responders, many of whom do not respond to currently available treatments. This study aimed to assess the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treating chronic PTSD in this population. METHODS: We did a randomised, double-blind, dose-response, phase 2 trial at an outpatient psychiatric clinic in the USA. We included service personnel who were 18 years or older, with chronic PTSD duration of 6 months or more, and who had a Clinician-Administered PTSD Scale (CAPS-IV) total score of 50 or greater. Using a web-based randomisation system, we randomly assigned participants (1:1:2) to three different dose groups of MDMA plus psychotherapy: 30 mg (active control), 75 mg, or 125 mg. We masked investigators, independent outcome raters, and participants until after the primary endpoint. MDMA was administered orally in two 8-h sessions with concomitant manualised psychotherapy. The primary outcome was mean change in CAPS-IV total score from baseline to 1 month after the second experimental session. Participants in the 30 mg and 75 mg groups subsequently underwent three 100-125 mg MDMA-assisted psychotherapy sessions in an open-label crossover, and all participants were assessed 12 months after the last MDMA session. Safety was monitored through adverse events, spontaneously reported expected reactions, vital signs, and suicidal ideation and behaviour. This study is registered with ClinicalTrials.gov, number NCT01211405. FINDINGS: Between Nov 10, 2010, and Jan 29, 2015, 26 veterans and first responders met eligibility criteria and were randomly assigned to receive 30 mg (n=7), 75 mg (n=7), or 125 mg (n=12) of MDMA plus psychotherapy. At the primary endpoint, the 75 mg and 125 mg groups had significantly greater decreases in PTSD symptom severity (mean change CAPS-IV total scores of -58·3 [SD 9·8] and -44·3 [28·7]; p=0·001) than the 30 mg group (-11·4 [12·7]). Compared with the 30 mg group, Cohen's d effect sizes were large: 2·8 (95% CI 1·19-4·39) for the 75 mg group and 1·1 (0·04-2·08) for the 125 mg group. In the open-label crossover with full-dose MDMA (100-125 mg), PTSD symptom severity significantly decreased in the group that had previously received 30 mg (p=0·01), whereas no further significant decreases were observed in the group that previously achieved a large response after 75 mg doses in the blinded segment (p=0·81). PTSD symptoms were significantly reduced at the 12-month follow-up compared with baseline after all groups had full-dose MDMA (mean CAPS-IV total score of 38·8 [SD 28·1] vs 87·1 [16·1]; p<0·0001). 85 adverse events were reported by 20 participants. Of these adverse events, four (5%) were serious: three were deemed unrelated and one possibly related to study drug treatment. INTERPRETATION: Active doses (75 mg and 125 mg) of MDMA with adjunctive psychotherapy in a controlled setting were effective and well tolerated in reducing PTSD symptoms in veterans and first responders. FUNDING: Multidisciplinary Association for Psychedelic Studies.
引用
- Mithoefer MC, Mithoefer AT, Feduccia AA, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018. PMID: 29728331. doi:10.1016/S2215-0366(18)30135-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。